Clinical Trial Update: Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED) [Phase 4]

View source ↗

Summary

A Phase 4 pediatric open-label trial comparing desloratadine 2.5 mg Reditab and cetirizine 5 mg chewable in children with allergies; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergies

Drugs mentioned

• Desloratadine 2.5 mg Reditab (SCH34117) (desloratadine)
• Zyrtec 5.0 mg Chewable Tablet (cetirizine)

Snippet

Sponsor: Organon and Co | Conditions: Allergies | Phase 4 | Status: COMPLETED | Results posted: 2010-07-05